CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia.
Prostate cancer (PRCa) is one of the most common causes of cancer death in men and determinants of PRCa risk remain largely unidentified. Benign prostatic hyperplasia (BPH) is found in the majority of ageing men and has been linked with PRCa. CYP3A4 may influence PRCa through its role in testosterone metabolism. This nested case-control study assessed a CYP3A4 single nucleotide polymorphism as a risk factor for developing PRCa in patients with BPH. The CYP3A4 variant allele identified men with BPH who are at increased risk of progressing to PRCa (odds ratio 6.3, 95% CI 2.3-17.3), providing a potential tool to assist prediction strategies for this disease.
Tayeb
Mohammed T
MT
Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen, UK.
Clark
Caroline
C
Sharp
Linda
L
Haites
Neva E
NE
Rooney
Patrick H
PH
Murray
Graeme I
GI
Payne
Simon N L
SN
McLeod
Howard L
HL
D000483:Alleles; D016022:Case-Control Studies; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008297:Male; D006899:Mixed Function Oxygenases / Q000235:genetics*; D016017:Odds Ratio; D011401:Promoter Regions, Genetic; D011470:Prostatic Hyperplasia / Q000235:genetics / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D012307:Risk Factors
D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human